High mobility group protein B1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13High mobility group protein B1 shows late clinical disease relevance led by COVID-19. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P09429. Start with COVID-19, then reuse UniProt P09429 as the stable protein anchor across project notes and exports.
Start with COVID-19, then reuse UniProt P09429 as the stable protein anchor across project notes and exports.
High mobility group protein B1 shows late clinical disease relevance led by COVID-19. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with COVID-19 because it currently carries late clinical support. Linked drugs include CD24FC. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyHigh mobility group protein B1
Review this target as High mobility group protein B1, mapped to UniProt P09429. Sequence length is 215 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats High mobility group protein B1 as ChEMBL target CHEMBL2311236, mapped to UniProt P09429. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether High mobility group protein B1 is the right protein anchor across sources, using UniProt P09429 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why COVID-19 is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | High mobility group protein B1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P09429 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | High mobility group protein B1 |
| UniProt Accession | P09429 |
| Component Type | Protein |
| Sequence Length | 215 aa |
High mobility group protein B1
Review this target as High mobility group protein B1, mapped to UniProt P09429. Sequence length is 215 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
High mobility group protein B1 shows late clinical disease relevance led by COVID-19. 2 more disease programs remain visible in the same review block.
Start review with COVID-19 because it currently carries late clinical support. Linked drugs include CD24FC. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4129393 | 8.83 | Kd | 1.48 | Preclinical |
| CHEMBL34259 | 7.62 | Kd | 24.0 | Approved |
| CHEMBL5653589 | 7.3 | Kd | 50.34 | Preclinical |
| CHEMBL4867183 | 6.1 | Kd | 800.0 | Preclinical |
| CHEMBL4875121 | 6.1 | Kd | 800.0 | Preclinical |
| CHEMBL424 | 6.0 | Kd | 1000.0 | Clinical |
| CHEMBL4858278 | 5.72 | Kd | 1900.0 | Preclinical |
| CHEMBL3752910 | 5.52 | Kd | 3008.4 | Preclinical |
| CHEMBL4860199 | 5.24 | Kd | 5800.0 | Preclinical |
| CHEMBL4858896 | 5.07 | Kd | 8600.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 19 | 17 | 5.8 |
| cell-based format | 13 | 0 | — |
| assay format | 2 | 1 | 7.0 |